DataMeds AI, Inc. reported second quarter 2026 financial results and provided a business update on August 17, 2026. Revenues grew 14% sequentially to $1.779 million, beating management projections, while the company recorded a net loss of $18.363 million compared to $6.672 million in the prior year period. The increased loss was driven by debt extinguishment expenses and general administrative costs. Key developments include a $6.5 million new funding round completed in June 2026, restructuring of $14.5 million in pre-existing debt, and the implementation of a 1-for-50 reverse stock split in May 2026 to address Nasdaq delisting risks. The company also announced lock-up agreements for approximately 49% of outstanding shares and plans to launch the 'Health Lives Here' consumer app with NFL Alumni Health in September 2026. DataMeds AI, Inc. operates in the healthcare technology industry, leveraging artificial intelligence and blockchain platforms to provide integrated healthcare solutions and data monetization services.

DataMEDS AI, Inc. entered into an Amended and Restated Letter of Intent to acquire or exclusively license QOLPOM-related intellectual property from EOS Technology Holdings and Scilex Holding Company, expand its PharmacyChain license with Datavault AI Inc., and acquire a controlling interest in Tollo Health through an exchange of membership interests with HealthBridge Advisors. The transaction consideration involves issuing common stock such that the acquiring entities would hold approximately 84.6% of the company on a fully diluted basis, while existing public shareholders would retain roughly 10.4%. The deal is subject to due diligence, financing, and regulatory approvals, including potential Nasdaq listing requirements.

DataMeds AI, Inc. updated the record date for the distribution of Dream Bowl 2026 Meme Coins to its stockholders from July 31, 2026, to August 7, 2026. The company announced that holders of common stock as of the new record date will receive fifty (50) meme coins per share, a change from the previously announced one-to-one ratio. The distribution date remains undetermined pending coordination with DataVault AI, Inc. As of July 27, 2026, there were approximately 2.8 million common shares outstanding, with significant lock-up agreements in place for majority shareholders. This filing relates to a health information technology company that integrates artificial intelligence and blockchain platforms into pharmacy and telemedicine services.

On July 20, 2026, Wellgistics Health, Inc. filed a Certificate of Amendment to change its corporate name to DataMeds AI, Inc., effective July 22, 2026. Concurrent with the name change, the company's Nasdaq trading symbol will change from "WGRX" to "MEDS" on July 22, 2026. The CUSIP number remains 949503205. The rebranding is intended to reflect the company's integration of AI and blockchain technology to optimize patient control of healthcare data. The company operates in the Health IT industry, focusing on the vertical integration of technology, pharmacy, and telemedicine business units.

On June 9, 2026, Nasdaq granted Wellgistics Health, Inc. an extension until October 12, 2026, to regain compliance with Listing Rule 5550(b)(1) regarding the Minimum Stockholders' Equity Requirement of $2.5 million, as the company reported stockholders' equity of $(12,447,801) as of December 31, 2025. To remedy this, the company is pursuing a combination with DataVault AI to create DelivMeds AI and intends to acquire a patent portfolio and a controlling stake in Tollo Health, targeting post-transaction stockholders' equity of approximately $40 million. Separately, Nasdaq notified the company on June 9, 2026, that it has regained compliance with the Minimum Bid Price Requirement of $1.00 per share. The company operates in the healthcare sector, providing health-related logistics and technology services.